Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05336786 · ClinicalTrials.gov registry record · Phase 3
Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)
A Phase 3 study of Prostate Carcinoma, sponsored by Thomas Jefferson University.
- Active
- Registry status
- Phase 3
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT05336786: Active Phase 3 study of Prostate Carcinoma, sponsored by Thomas Jefferson University.
NCT05336786 is a Phase 3 study of Prostate Carcinoma that is active but no longer recruiting, run by Thomas Jefferson University. The registered enrollment target is 70 participants, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05336786, a Phase 3 study of Prostate Carcinoma, is active but no longer recruiting, sponsored by Thomas Jefferson University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity appears on ultrasound images as tiny gas-filled microbubbles. These microbubbles are about the size of a red blood cell and do not stay in a patient's body for more than several minutes, where they are excreted from the lungs and exhaled back into the air when breathing. Definity may enhance ultrasound images of the prostate and help doctors identify prostate cancer on ultrasound images.
Conditions Studied
Interventions
- DRUG Perflutren Lipid Microspheres
- PROCEDURE Ultrasound
Study Locations (2)
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Other
- Amsterdam University Medical Centers - Amsterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2022-06-15 |
| Est. Completion | 2026-05-26 |
| Phase | Phase 3 |
What the registry record for NCT05336786 still lists
NCT05336786 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Prostate Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Perflutren Lipid Microspheres is the first listed.
NCT05336786 reports a single indexed study location in Pennsylvania, Other.
Frequently Asked Questions
What is clinical trial NCT05336786 about?
NCT05336786 is a clinical study titled "Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)". This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity ap...
What is the current status of trial NCT05336786?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2022-06-15. Estimated completion is 2026-05-26.
What conditions does trial NCT05336786 study?
This clinical trial studies the following conditions: Prostate Carcinoma.
What interventions are being tested in trial NCT05336786?
The interventions under investigation include: Perflutren Lipid Microspheres (DRUG), Ultrasound (PROCEDURE).
Who is sponsoring clinical trial NCT05336786?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05336786 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05336786's enrollment target sits among peer trials
70 37th of 59 higher than 23 of 59 other Prostate Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer
RECRUITING · Phase 3
-
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
ACTIVE NOT RECRUITING · Phase 3
-
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
RECRUITING · NA
-
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
RECRUITING · Early Phase 1
-
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
RECRUITING
-
An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI